Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
RegulatoryapprovedPasatruSohonosPositive
AI Analysis
Summary
Regeneron received FDA approval for Pasatru, the second approved treatment for fibrodysplasia ossificans progressiva in the U.S., positioning the company to compete with Ipsen's previously approved Sohonos in this rare bone disease market.
Outcome Details
FDA approval for Pasatru in fibrodysplasia ossificans progressiva; second drug approved in the U.S. for this indication following Ipsen's Sohonos in 2023
Importance:8/10
Sentiment:
0.75
FDA approvalrare diseasefibrodysplasia ossificans progressivacompetitive approval
Related Companies
Read the original article
Published by BioSpace on August 20, 2026 12:32 PM